The Center was recently honored by JDRF for its pioneering work in the development of Artificial Pancreas technology.


What is Type 1 Diabetes?

Type 1 diabetes is a chronic disease affecting an estimated 11-22 million people worldwide. It caused by the autoimmune destruction of insulin-producing cells in the pancreas and results in the loss of the ability to maintain blood glucose homeostasis.

Currently, diabetics manage their condition by self-monitoring blood glucose, counting carbohydrates and taking insulin either with multiple daily injections or via insulin pump. Using these techniques, only about 25% of diabetics meet the standard for good glycemic control. Failure to achieve tight glycemic control is associated with a plethora of long-term complications including heart disease, kidney disease and neuropathy. Poor blood glucose control has also been shown to cause low energy, mood swings and cognitive disruptions on a daily basis.

Our Research

DiAsHSPicResearchers at the CDT aim to make diabetes management easier and more effective through the development of automated insulin delivery. By implementing advanced algorithms that use continuous glucose monitor data to automatically adjust insulin delivery, we have shown that time-in-range can be increased while simultaneously reducing the occurrence of hypoglycemia. Our smartphone-based automated insulin delivery system, the DiAs (Diabetes Assistant), has been used by 425 subjects for a cumulative operation time of more than 18 years.

If you or a loved one would like to participate in one of our clinical studies, please click here.